Cantor Fitzgerald analyst Li Watsek initiated coverage of Compass Therapeutics (CMPX) with an Overweight rating and no price target The company is is approaching readouts for its lead bispecific antibody, tovecimig, in late Q1, the analyst tells investors in a research note. Cantor believes the stock “has an asymmetrical setup” into the readout. It believes the Street underestimates the peak sales of tovecimig in second-line biliary tract cancer, which it thinks could reach $712M by 2032.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics initiated with a Buy at Canaccord
- Compass Therapeutics initiated with an Outperform at Citizens JMP
- Compass Therapeutics’ CTX-10726: A Promising Leader in the Competitive PD-1 and VEGF Markets
- Compass Therapeutics Reports Q3 2025 Financial Results
- Positive Outlook for Compass Therapeutics: Buy Rating Justified by Promising Developments and Strong Financial Position